Venture&Growth
Venture&Growth
All Portfolio items
See full Venture&Growth portfolio
Splice Bio is a biotech company based on intein technologies developed in the Muir Lab at Princeton University. They are working with their proprietary platform to address key limitations of current gene therapy approaches to treat patients in need. The company is building a product pipeline of gene therapies targeting inherited retinal diseases and other severe genetic diseases for which there is no cure.
More Splice Bio news
Gilde Healthcare company SpliceBio enters $216 million Gene Therapy collaboration with Spark Therapeutics
Gilde Healthcare invests in Eur 50M series A round of Spanish Gene Therapy company SpliceBio
Lumeon
UK-based HealthTech company offering care pathway solutions
Argá Medtech
Argá Medtech is developing the next generation non-thermal cardiac ablation system. The system for treating...
AM-Pharma
AM-Pharma is a Dutch biopharmaceutical company developing a biotherapeutic for the treatment of Sepsis Associated...